Objective: The aims were (1) to quantitate angiotensin I to II conversion on the endothelial surface and at deeper sites in isolated arteries, (2) to assess whether the angiotensin II that is formed at deeper sites is released into the vascular lumen, and (3) to examine whether enzymes other than angiotensin converting enzyme (ACE) are involved in vascular angiotensin I to II conversion. Methods: Metabolism of [""I]-angiotensin I was studied in isolated perfused porcine coronary and carotid arteries after luminal administration of the labelled peptide (in the perfusion fluid) and after adventitial administration (in the organ bath). Measurements were made both in the presence and in the absence of captopril. Results: ['*'I]-angiotensin II was a major metabolite and its formation was virtually completely blocked by captopril, after both luminal and adventitial administration of ['251]-angiotensin I. In coronary arteries (n = S), the ['251]-angiotensin I to II conversion rate after adventitial administration was about half that after luminal administration. In coronary arteries (n = 6) the conversion rate after adventitial administration was lo-20 times lower than after luminal administration. Degradation of 
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Objective: The aims were (1) to quantitate angiotensin I to II conversion on the endothelial surface and at deeper sites in isolated arteries, (2) to assess whether the angiotensin II that is formed at deeper sites is released into the vascular lumen, and (3) to examine whether enzymes other than angiotensin converting enzyme (ACE) are involved in vascular angiotensin I to II conversion. Methods: Metabolism of [""I]-angiotensin I was studied in isolated perfused porcine coronary and carotid arteries after luminal administration of the labelled peptide (in the perfusion fluid) and after adventitial administration (in the organ bath). Measurements were made both in the presence and in the absence of captopril. Results: ['*'I]-angiotensin II was a major metabolite and its formation was virtually completely blocked by captopril, after both luminal and adventitial administration of ['251 ]-angiotensin I. In coronary arteries (n = S), the ['251 ]-angiotensin I to II conversion rate after adventitial administration was about half that after luminal administration. In coronary arteries (n = 6) the conversion rate after adventitial administration was lo-20 times lower than after luminal administration. Degradation of T he classical view of angiotensin II, the most important biologically active product of the renin-angiotensin system, as a circulating hormone has been challenged in recent years. Previously it was thought that angiotensin II was derived solely from the conversion of circulating angiotensin I by membrane bound angiotensin converting enzyme (ACE) of the vascular endothelium. This enzyme is identical with kininase II. However, there is now evidence that many tissues, including heart and blood vessels, contain a complete renin-angiotensin system"3 and that angiotensin I and angiotensin II may also be generated locally, outside the circulating plasma.4-7 There is even good evidence that in a number of vascular beds angiotensin I production at tissue sites may contribute to the circulating levels of angiotensin I and II.5 ' Angiotensin II produced in vascular tissue from in situ synthesised angiotensin I or from angiotensin I taken up from the circulation may serve functions other than the regulation of vascular tone. It may for instance contribute to the development of vascular hypertrophy. ' The formation of angiotensin II in the vessel wall may not depend on endothelial ACE only. Endothelium denuded rat aortic rings contain ACE activity, as determined with a synthetic tripeptide substrate.' ACE has also been demonstrated in endothelium denuded porcine coronary arteries by using ['251 ]-labelled angiotensin I as substrate.'" In addition, angiotensin I has been found to contract endothelium denuded rat aortic rings." In support of these findings, ACE activity has been shown in cultured rat aortic smooth muscle cells.12
Several enzymes other than ACE have been described which can convert angiotensin I to angiotensin II in vitro."-'h A chymostatin sensitive angiotensin II generating enzyme (CAGE), capable of catalysing angiotensin I to II conversion, has been isolated from aortic tissue of dog, monkey, and man.17 " This enzyme is localised mainly in the adventitia,'" and is thought to be identical with an angiotensin II forming chymase which has recently been discovered in human heart tissue.'" *' Human heart chymase is a serine proteinase with high specificity for angiotensin I. Chymase mRNA is expressed in endothelial cells and in mast cells2' and may be induced by vascular injury. 22 We decided to compare angiotensin I metabolism after luminal and adventitial administration of [""I]-labelled angiotensin I to isolated perfused porcine arteries. The aim of the present study was (1) to quantitate angiotensin I to II conversion both on the endothelial surface and at deeper sites in isolated arteries, (2) to assess whether the angiotensin II that is formed at deeper sites is released into the vascular lumen, and (3) to examine whether angiotensin converting enzymes other than ACE are involved in vascular angiotensin I to II conversion.
Blood vessel preparation

Methods
Carotid and left anterior descending coronary arteries were obtained from 20 pigs (weight 16-24 kg, crossbred Yorkshire X Landrace) during anaesthesia with 160 mg.kg-' CL chloralose, which was given into the superior caval vein, followed by a continuous intravenous infusion of low dose sodium pentobarbitone (5 mg.kg-'.h"). The pigs had been used for acute pharmacological experiments involving intravenous saline or calcitonin gene related peptide infusions. All experiments were performed in accordance with the Guiding principles in the care and use of animals as approved by the American Physiological Society and under the regulations of the animal care committee of the Erasmus University, Rotterdam, The Netherlands.
The vessels (diameter 2-3 mm) were dissected free from surrounding tissue, and 1-2 cm sections without side branches were mounted horizontally in a double jacketed 4 ml organ bath containing Krebs buffer (composition in mmol.litre-': NaCl 118, KC1 4.7, CaCl, 2.5, MgSO, 1.2, NaHCO, 25, KH,PO, 1.2, and glucose 8.3) which was continuously gassed with 95% OZ and 5% COZ at 37°C as described by Hulsmann et al.'* The vessels were perfused with carbogenated Krebs buffer from a 6 ml reservoir kept at 37°C in a water bath, using a roller pump. The flow was kept at 1 ml.min'. The perfusate was collected in the reservoir and reperfused through the vessel, thus creating a closed perfusion circuit (fig 1) . This set up allowed us to obtain samples from both the reservoir ("Ferfusate") and the organ bath ("bath fluid") after the addition of ['* I]-angtotensin I to either the perfusate reservoir or the organ bath.
Preparation qf radiolabelled angiotensins Monoiodinated ['251]-angiotensin I was prepared with the chloramine-T method and purified as described previously.5 The specific radioactivity of the ['*51]-angiotensin I preparation was 3.6 X IO6 countsmin' (cpm) pmol-' (74 kBq.pmol-'). [".I]-labelled preparations of angiotensin II, angiotensin III, angiotensin-(3-8) angiotensin-(4-8), angiotensin-(2-lo), angiotensin-( t-7). and tyrosine were also made.5 %taration and measurement of radiolabelled angiotensins [ --I]-angiotensin I and its metabolites were extracted from the samples obtained during the experiment (see below) by reversible adsorption to octadecylsilyl silica (SepPak Cl 8, Waters). The SepPak cartridges were conditioned with 4 ml methanol and equilibrated with 2 X 4 ml of cold water. Samples were passed through the cartridge at 4°C followed by a wash with 2 X 4 ml of cold water. Adsorbed angiotensins were eluted with 3 ml methanol into polypropylene tubes and the methanol was evaporated under vacuum rotation at 4°C using a Savant Speed Vat concentrator.
Artery
Roller pump ? Figure 1 Schematic presentation of the experimental set up. A 1-2 cm vessel segment is mounted in a double jacketed organ bath that contains Krebs buffer at 37°C. The buffer is continuously gassed with 95% O2 and 5% COL. The vessel lumen is constantly pe@sed with gassed Krebs bufler from a reservoir kept in a water bath at 37"C, using a roller pump. Volume of the bath was 4 ml. Total volume of the reservoir including pump and connecting cannulas was 6 ml. ['251]-labelled angiotensin I was added to the reservoir ("luminal administration") or the organ bath ("adventitial administration ").
[ "51]-labelled angiotensins were separated by reversed phase high pressure liquid chromatography (HPLC), according to the method of Nussberger et a1?3 using a Nucleosil Cl8 steel column of 250 X 4.6 mm and 10 pm particle size. Mobile phase A was 0.085% orthophosphoric acid containing 0.02% sodium azide. Mobile phase B was methanol. The flow was 1.5 mlmin-' and the working temperature was 45°C. SepPak methanol extracts were dissolved in 100 p,l of HPLC solvent (mobile phase A) and injected. Elution was performed as follows: 65% A/35% B from 0 to 9 mitt, followed by a linear gradient to 45% A/55% B until 18 min. The eluate was collected in 20 s fractions into polypropylene tubes, and the concentrations of ['*51]-a.ngiotensin I and its radiolabelled metabolites in the HPLC fractions were measured in the gamma counter.
There was virtually complete recovery of radioactivity after SepPak extraction. Moreover, more than 95% of ["'I]-angiotensin I or II that had been added to SepPak extracts was recovered after HPLC separation. Results of [' 'I]-angiotensin I and II measurements were therefore not corrected for the small losses during extraction and HPLC separation.
Experimental protocol
The blood vessel preparations were allowed to equilibrate for 30 min. In each carotid and coronary artery two experiments were performed. In one experiment approximately lo6 cpm ['*'I]-angiotensin I were added to the perfusate reservoir ("luminal administration"). Samples of 100 pl were taken from both organ bath and reservoir at t = 0, 1, 2, 5, 10, 20, and 40 min after the addition of ["51]-angiotensin I, and were immediately mixed with 10 ~1 inhibitor solution containing 125 mM disodium EDTA and 25 mM 1, IO-phenanthroline, to inhibit ACE and angiotensinases, respectively. The samples were stored at -70°C and assayed within one week. In the second experiment ["'I]-angiotensin I (approximately lo6 cmp) was added to the organ bath ("adventitial administration"), after which 100 pl samples were taken from both organ bath and reservoir at t = 0, 5, 10, 20, 30, and 40 min. The samples were immediately mixed with inhibitor solution as described above, and stored at -70°C. The two experiments were performed in random order, and between the two experiments the Krebs buffer in the organ bath and reservoir was refreshed several times in order to wash out all radioactivity.
In a second series of experiments, captopril was added in a concentration of 0.4 mM before the addition of [ *'I]-angiotensin I. Thi\ concentration of captopril had previously been shown to inhibit ACE but not other enzymes involved in the metabolism of angiotensin I."
After completion of the experiments the length of the vessel segments was measured. The vessels were then blotted on dry paper and weighed. The wet weight of the coronary artery segments (n= 11) did not differ from that of the carotid artery segments (n=9): 70(SEM 7) mg and 99( 11) mg, respectively, and the lengths were likewise similar: 1.5(0. I) and I .6(0.2) cm.
Reagents
[IleS]-angiotensin-( I-10) decapeptide (angiotensin I), [Ile5]-angiotensin-( l-8) octapeptide (angiotensin II), and [Ile5]-angiotensin-(2-8 J heutaueutide (aneiotensin III) were from Bachem. IIle51-anuiotensin-(21ioj nonapeptide (angiotensin-(2-10)) was from _ Senn CYhemicals.
[IleS]-angiotensin-(3-8) hexapeptide (angiotensin-(3-8) 
heptapeptide (angiotensin-( l-7)), and tyrosine were from Peninsula Laboratories. Captopril was obtained from Bristol-Myers Squibb. Methanol, ortho-phosphoric acid (both analytical grade), and I. IO-phenantroline were purchased from Merck. Water for HPLC was prepared with a Milli-Q system from Waters.
Calculations ['251 ]-angiotensin I is eliminated either by conversion to ['?I-angiotensin II by ACE or other angiotensin converting enzymes, or by breakdown to small biologically inactive peptides by various other enzymes. We refer to the latter process as "degradation" of ['Z51]-angiotensin Lz4 The first order rate constants for degradation and conversion of ["'I]-angiotensin I are denoted as k, and kz. respectively. The rate constant for ["'I]-angiotensin 1 elimination (k,) is taken to be equal to the sum of the first order rate constants for conversion and degradation.
The metabolism of ['251]-angiotensin I in a closed perfusion circuit can be described by the equation for a first order process, so that k,, can be calculated as follows: Finally, k2 can be obtained by subtracting k, (calculated with formula 2) from k, (calculated with formula 1).
['251]-angiotensin I metabolic clearance rates due to degradation plus conversion or due to degradation or conversion seuaratelv were calculated by multiplying k,-+ k, , k, , or k, respectively w&h the 'volume of distribution (6 ml for luminal administration. 4 ml for adventitial administration).' No corrections were made for the small volume changes that occurred as a consequence of fluid sampling for angiotensin measurements.
The percentage of ['251]-angiotensin I metabolism due to conversion is defined as follows:
Contribution of conversion to metabolism (%) = [k2/(kl + k,)].lOO.
Statistics All data are reported as mean(SEM). Differences between carotid and coronary arteries and differences between exoeriments with and without captopril were evaluated for statistical signi&.nce (P c 0. ['251 ]-angiotensin I administration tended to be higher than the MCR during adventitial administration, but the difference was not significant. The MCR due to conversion was higher with luminal administration than with adventitial administration in the carotid arteries (fig 6 and table) .
The percentage of [""I]-angiotensin I metabolism that could be attributed to ["'I]-angiotensin I to II conversion amounted to 45(SEM 4)% (luminal administration, n = 8) and 37(3)% (adventitial administration, n = 8) in coronary arteries, and to 62(5)% (luminal administration, n = 6) and 47(X)% (adventitial administration, n = 6) in carotid arteries. With captopril, the percentage of ['2SI]-angiotensin I metabolism that could be attributed to ['251 ]-angiotensin I to II conversion amounted to 16(7)% (luminal administration, n = 3; P < 0.05 for the difference with the experiments in the absence of captopril) and 9(4)% (adventitial administration; P < 0.05) in coronary arteries, and to 15(l)% (luminal administration, n = 3; P < 0.05) and 10( 1)% (adventitial administration; PcO.05) in carotid arteries. Thus after captopril more than 85% of ["'I]-angiotensin I metabolism in the coronary and carotid arteries was due to degradation.
Discussion
Previous studies have shown that the vessel wall contains multiple enzymes, for example tissue plasminogen activator, tonin, cathepsin A, cathepsin G, CAGE, and chymase, which are capable of converting angiotensin I to angiotensin II in vitro and which cannot be blocked by ACE inhibitors.13-19 26 27 However, in most of these studies the conversion of angiotensin I to angiotensin II was studied using vascular tissue homogenates and it is not known to what extent homogenisation of the tissues may cause the release of several cellular enzymes that are not normally involved in the metabolism of angiotensins. We have observed that angiotensin I and II are much more rapidly Vascular angiotensin I metabolism 793 degraded in cardiac tissue homogenates than in the intact tissue.28 In published studies in which intact vessels were used angiotensin II formation was either not quantitated directly26 or measured after adding highly unphysiological amounts (50 pg per vessel) of angiotensin I.*' In the present study we investigated angiotensin I metabolism under more physiological conditions, using intact segments of porcine coronary and carotid arteries, perfused with carbogenated Krebs buffer at 37°C. This model allowed us to administer angiotensin I to the blood vessel in the perfusion fluid (luminal application) or in the surrounding bath fluid (adventitial application). With luminal application, angiotensin I is primarily exposed to the vascular endothelium. Adventitially administered angiotensin I -which most probably corresponds to the angiotensin I that is formed in the vessel wall in the in vivo situation -may also reach the endothelium, but is primarily exposed to enzymes present in the media or adventitia. With both ways of administration, one would expect that endothelially produced angiotensin I metabolites would appear in the perfusate. These findings. lend support to the concept that vascular conversion of angiotensin I is not limited to the luminal endothelial surface. Our present observation that little angiotensin I and II passed through the wall of the carotid and coronary arteries from the lumen to the bath and vice versa, together with our previous work' indicating rapid exchange between the angiotensins in circulating blood and the tissue interstitial fluid, is compatible with the idea that the exchange occurs mainly at the capillary level. There seems to be little accumulation of angiotensins in the present experiments because only low levels of radioactivity were found in the vessel segments at the end of the perfusion.
The conversion that occurs on the endothelial surface as well as at deeper sites appears to be mediated by ACE, because the ACE inhibitor captopril caused nearly complete inhibition of angiotensin II formation at these sites. Therefore, in the pig, enzymes other than ACE do not seem to play a major role in the conversion of circulating angiotensin I.
The evidence provided by our observations on perfused arteries that ACE dependent angiotensin I to II conversion is not limited to the endothelium extends previous studies in which the formation of ['*'I]-angiotensin II was followed during incubation of tissue pieces from endothelium denuded porcine coronary arteries with ['251]-angiotensin I." From these studies it was calculated that approximately 25% of the vascular ACE was extraendothelial. Similar findings have been reported for the rat aorta; de-endothelialisation of this vessel resulted in a 30% decrease in ACE activity of aortic tissue homogenates, suggesting that 70% of rat aortic ACE is situated outside the endothelium.' The higher contribution of extraendothelial sites to angiotensin I to II conversion in the rat aorta might be related to the localisation of ACE in the smooth muscle layer. " Radioligand binding studies have shown that ACE in the porcine carotid artery and in the by guest on December 9, 2014 Downloaded from human internal mammary artery is found mainly in the endothelial layer and in the adventitia.29 3o These species differences in ACE localisation may partially explain the conflicting data concerning the effects of ACE inhibitors on myointimal proliferation after vascular injury. In the rat, the myointimal proliferative response to endothelial damage of the carotid artery was prevented by ACE inhibitor treatment.3' This could not be confirmed in the pig3' and likewise in humans the use of ACE inhibitors for the prevention of restenosis after angioplasty proved to be ineffective.3' 34 It should be noted, however, that the doses used in the rat experiments were up to 70 times higher than those used in man.
The possibility that our results might be explained by endothelial ACE activity of the adventitial vasa vasorum29 must be addressed. sites. Blood derived angiotensin I and locally formed angiotensin I are most probably metabolised differently, since blood derived angiotensin I has to pass the endothelial barrier which is rich in converting and degrading enzymes.
Our study clearly shows that ACE present in the adventitia or media is functionally active. One characteristic component of the adventitia is the noradrenergic nerve endings which are located at the adventitial-medial border. Angiotensin II produced by ACE in the vicinity of the nerve endings could act presynaptically to facilitate noradrenaline release. Angiotensin II mediated facilitation of neurotransmitter release has been shown in a number of vascular preparations. 35 " It is further possible that angiotensin II formed locally within the vascular media is involved in the induction of medial hypertrophy.* Key terms: angiotensin; angiotensin converting enzyme; captopril; endothelium; renin: blood vessel wall.
